Here’s what you need to know.
(Want to get this briefing by email? Here’s the sign-up.)
Mr. Trump and his Republican allies vowed on Monday to pursue and even punish those responsible for the special counsel’s Russia investigation now that it has ended without implicating him or his campaign.
The president denounced “treasonous” people who should be investigated themselves, and the chairman of the Senate Judiciary Committee suggested a separate inquiry into potential anti-Trump bias at the F. B. I.
The attorney general: William Barr’s decision to declare that Mr. Trump had not committed a crime — despite the fact that the special counsel, Robert Mueller, stopped short of exonerating the president — has renewed a debate about the role of American law enforcement in politically charged investigations.
The special counsel: Now that his report has been filed, Mr. Mueller is poised to return to civilian life as a figure of mystery and fascination.
The news media:Journalists faced bipartisan criticism after the special counsel found that the Trump campaign had not conspired with Russia. Dean Baquet, the executive editor of The Times, said. “We wrote a lot about Russia, and I have no regrets. It’s not our job to determine whether or not there was illegality.”
The Daily: In today’s episode, a reporter discusses Mr. Barr’s determination that Mr. Trump had not illegally obstructed justice.
A plan to install electronic tolls for vehicles entering the busiest stretches of Manhattan would make the city the first in the U. S. to use congestion pricing.
State lawmakers agreed on Monday that the plan was necessary to help pay for much-needed repairs to the subway system. Congestion pricing has helped unclog streets in places like London, Singapore and Stockholm, although the plans have been criticized as an unfair tax.
What’s next: Many specifics, including the exact price for entering Manhattan’s main business district, are still being considered. The leader of the State Assembly seemed confident on Monday that a deal could be reached before a budget deadline on April 1.
For decades, the Sackler family has generously supported museums around the world, as well as medical and educational institutions including Columbia and Oxford.
But some beneficiaries are reconsidering their relationship with the family because of its ties to Purdue Pharma, the maker of the frequently abused painkiller OxyContin. More than 200,000 people in the U. S. have died from overdoses involving OxyContin and other opioids in the past two decades.
Background: The scrutiny of the Sacklers is part of a broader reckoning in the museum world about who sits on boards and bankrolls programs.
